Erudio Healtherudio.com
Sponsor
Astellas trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Astellas yet. Erudio has found public clinician commentary on 15 clinical trials sponsored by Astellas, including EV-103, EV-201, EV-301 and ILUSTRO. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Astellas Pharma Global Development, Inc.; Astellas Pharma Inc). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| EV-103 NCT03288545 · Astellas Pharma Global Development, Inc. DeepView → | urothelial cancer | Phase 1/Phase 2 | Deep | View | |||
| EV-301 NCT03474107 · Astellas Pharma Global Development, Inc. DeepView → | previously treated locally advanced or metastatic urothelial cancer | Phase 3 | Deep | View | |||
| ILUSTRO NCT03505320 · Astellas Pharma Global Development, Inc. DeepView → | CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Deep | View | |||
| EV-201 NCT03219333 · Astellas Pharma Inc DeepView → | locally advanced or metastatic urothelial cancer | Phase 2 | Deep | View | |||
| EV-209 NCT07475806 · Astellas Pharma Global Development, Inc. DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| EV-309 NCT07566156 · Astellas Pharma Global Development, Inc. DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| LUCERNA NCT06901531 · Astellas Pharma Global Development, Inc. DeepView → | HER2-negative CLDN18.2-positive PD-L1-positive advanced gastric or GEJ adenocarcinoma | Phase 3 | Deep | View | |||
| EV-302 NCT04223856 · Astellas Pharma Global Development, Inc. DeepView → | untreated locally advanced or metastatic urothelial cancer | Phase 3 | Deep | View | |||
| GLEAM NCT03816163 · Astellas Pharma Global Development, Inc. DeepView → | first-line CLDN18.2-positive metastatic pancreatic adenocarcinoma | Phase 2 | Deep | View | |||
| EV-202 NCT04225117 · Astellas Pharma Global Development, Inc. DeepView → | locally advanced or metastatic malignant solid tumors | Phase 2 | Deep | View | |||
| EV-104 NCT05014139 · Astellas Pharma Global Development, Inc. StandardView → | non-muscle invasive bladder cancer | Phase 1 | Standard | View | |||
| NCT05382559 NCT05382559 · Astellas Pharma Inc FocusedView → | KRAS G12D locally advanced or metastatic solid tumors | Phase 1 | Focused | View | |||
| ARCHES NCT02677896 · Astellas Pharma Global Development, Inc. FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT07409272 NCT07409272 · Astellas Pharma Global Development, Inc. FocusedView → | KRAS G12D-mutated metastatic pancreatic adenocarcinoma | Phase 3 | Focused | View | |||
| SPOTLIGHT NCT03504397 · Astellas Pharma Global Development, Inc. FocusedView → | Not given | Phase 3 | Focused | View | |||